Lazard Asset Management
EBS icon

Lazard Asset Management’s Emergent Biosolutions EBS Stock Holding History

Lazard Asset Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,344
Closed -$30K – 2350
2025
Q1 		$30K Sell
6,344
-48,959
-89% -$405K ﹤0.01% 2076
2024
Q4 		$528K Buy
55,303
+46,676
+541% +$428K ﹤0.01% 1351
2024
Q3 		$72K Sell
8,627
-92,831
-91% -$844K ﹤0.01% 1849
2024
Q2 		$691K Buy
+101,458
New +$437K ﹤0.01% 1081
2023
Q4 		– Sell
-26,782
Closed -$91K – 2303
2023
Q3 		$91K Buy
+26,782
New +$148K ﹤0.01% 1667
2023
Q1 		– Sell
-4,783
Closed -$56K – 2362
2022
Q4 		$56K Buy
+4,783
New +$74K ﹤0.01% 1748
2022
Q3 		– Sell
-1,782
Closed -$55K – 2375
2022
Q2 		$55K Hold
1,782
– – ﹤0.01% 1765
2022
Q1 		$73K Buy
+1,782
New +$78.6K ﹤0.01% 1544
2021
Q4 		– Sell
-1,261
Closed -$63K – 2325
2021
Q3 		$63K Sell
1,261
-231
-15% -$14K ﹤0.01% 1573
2021
Q2 		$93K Sell
1,492
-369,646
-100% -$23.7M ﹤0.01% 1371
2021
Q1 		$34.5M Buy
371,138
+21,814
+6% +$2.23M 0.04% 327
2020
Q4 		$31.3M Buy
349,324
+15,206
+5% +$1.4M 0.04% 343
2020
Q3 		$34.5M Buy
334,118
+5,283
+2% +$570K 0.05% 292
2020
Q2 		$26M Sell
328,835
-45,935
-12% -$3.42M 0.04% 324
2020
Q1 		$21.7M Sell
374,770
-164,285
-30% -$9.47M 0.04% 295
2019
Q4 		$29.1M Sell
539,055
-57,140
-10% -$3.1M 0.04% 281
2019
Q3 		$31.2M Sell
596,195
-123,435
-17% -$5.75M 0.05% 252
2019
Q2 		$34.8M Buy
+719,630
New +$34.5M 0.06% 240

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OHA
Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Lazard Asset Management's EBS Position: Q2 2025 in Review

Lazard Asset Management sold out of Emergent Biosolutions (EBS) in Q2 2025, closing a stake of 6,344 shares — an estimated $30K sold.

Lazard Asset Management first reported a position in EBS in Q2 2019 and held it in 18 quarters. The position peaked at $34.8M in Q2 2019. 161 funds tracked by Wall St. Rank hold EBS as of Q2 2025.

  • Lazard Asset Management reported no remaining Emergent Biosolutions position as of Q2 2025 after selling out during the quarter.
  • Lazard Asset Management sold 6,344 Emergent Biosolutions shares in Q2 2025, an estimated $30K.
  • Lazard Asset Management first reported a position in Emergent Biosolutions in Q2 2019 and held it in 18 quarters.
  • Lazard Asset Management's Emergent Biosolutions position peaked at $34.8M in Q2 2019.
  • 161 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2025.

Based on Lazard Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.